

Patient Dosimetry Audit for Establishing Local Diagnostic Reference Levels for Nuclear Medicine CT

CT Users Group Meeting

20th October 2016, Manchester Conference Centre

Ngonidzashe Michael Katsidzira

Matthew Gardner

RRPPS

University Hospitals Birmingham

NHS Foundation Trust

Contents

- Background
- Methods
- Results
- Discussions
- Conclusion
- Acknowledgements
- References

NB: This work will be submitted for publication imminently

Background

- Diagnostic Reference Levels (DRLs) provide a useful tool for monitoring patient doses
- It is a legislative requirement to establish Local DRLs (LDRLs) (UK¹ and Europe²)
- DRLs (Local and National) are well established in diagnostic radiology but not a common practice in Nuclear Medicine (NM) CT
- NDRLs are available for NM in terms of administered activity³ (no information on CT component)
- Previous work has been carried out to establish DRL for PET/CT^{4,5}

Background (cont...)

Table 1: IPEM Working Party Proposed NDRLs⁶ for common NMCT examinations

Examination Type	CT Purpose	Proposed NDRLs	
		CTDI_{vol} (mGy)	DLP (mGycm)
PET half body	Localisation	4.3	400
Parathyroid	Localisation	5.6	170
Bone	Localisation	5.6	180
Octreotide/MIBG	Localisation	5.4	240
Thyroid post ablation	Localisation	5.9	210
SPECT/PET cardiac	Attenuation Correction	2.0	34

Background (cont...)

- The aim of this work was to establish a system for NMCT in terms of
 - ✓ patient dosimetry audit
 - ✓ setting up LDRLs
- Patient dosimetry for NMCT presented a number of difficulties which may not be encountered for diagnostic radiology CT

Background (cont...)

- For diagnostic radiology CT, data are divided according to body region only (e.g. Lumbar Spine)
- For NMCT, data were divided according to ;
 - ✓ examination type (e.g. Bone)
 - ✓ body region
 - ✓ dose modes
- Obtaining sufficient patient numbers proved challenging for NMCT due to the above data division

Background (cont...)

Table 2: CT dose modes developed for Nuclear Medicine at the Queen Elizabeth Hospital Birmingham

Dose Mode	CT Purpose	kV	Quality Reference mAs*
Low	Attenuation Correction	130	10-16
Moderate	Localisation	130	40
Standard	Diagnostic CT	130	150
Metal	Patients with Orthopaedic Implants	130	330

*values are approximate as actual value depends on body region

Methods

- Data have been collected from examinations performed on
 - ✓ Two SPECT/CT scanners (Siemens Symbia T16 and T)
 - ✓ PET/CT scanner (Siemens Biograph mCT Flow)
- Data collection periods
 - ✓ SPECT/CT (November 2014 to July 2016)
 - ✓ PET/CT (April to August 2016)
- Examination data capture
 - ✓ Computed Radiological Information System (CRIS)
 - ✓ Paper records (manually recorded by NM Technologists)

Methods (cont...)

- CRIS downloads provided information on the
 - ✓ examination type
 - ✓ date of birth
 - ✓ date of examination
 - ✓ Dose Length Product (DLP)
- CRIS provided sufficient information to perform dose analysis for
 - ✓ PET/CT examinations
 - ✓ Cardiac SPECT/CT examinations

(as these are not associated with different dose modes and body regions)

Methods (cont..)

- The mean and standard deviation of DLPs for common NMCT examinations were then calculated
- Data were subjectively assessed and any obvious outliers removed before analysis
- Paediatric data were also identified and removed before analysis
- Only examinations with 10, or more, patients were analysed
- LDRLs will be set based on the mean DLP

Methods (cont...)

- Paper records provided additional information for SPECT/CT (excluding Cardiac) examinations
 - ✓ body region
 - ✓ dose mode
 - ✓ scanner
- The CRIS data and paper records were matched using the patient identification number and examination date found on both records
- For common SPECT/CT examinations, data were divided in terms of the *examination type, body region, scanner and dose mode*

Results

Table 3 : Comparison between mean DLP and IPEM WP proposed NDRLs⁶ for Bone SPECT/CT examinations for different body regions and dose modes

Examination Type	Body Region	Scanner	No. of Patients	Dose Mode	DLP (mGy cm)		
					Mean DLP	Standard Deviation	Proposed NDRLs
<i>Bone</i>	Pelvis	T	15	Moderate	105	40	180
	T-Spine	T	13	Moderate	133	40	180
	T-Spine/L-Spine	T	15	Moderate	124	26	180
	L-Spine	T	47	Moderate	107	33	180
	L-Spine	T16	24	Moderate	170	70	180
	L-Spine	T16	33	Standard	634	226	
	L-Spine	T16	11	Metal	1045	426	
	Feet/Ankles	T	10	Standard	153	44	
	Feet/Ankles	T16	32	Standard	221	39	
	Pelvis	T16	11	Standard	558	111	
	Pelvis	T16	34	Metal	1359	322	
	Knees	T16	10	Standard	230	130	
	Knees	T16	111	Metal	913	285	
	T-Spine/L-Spine	T16	24	Standard	704	306	

Moderate - Localisation, **Standard** - Diagnostic CT, **Metal** - Patient with orthopaedic implants

Results (cont..)

Table 4 : Comparison between mean DLP and proposed NDRLs⁶ for different examination types body region and dose modes


Examination Type	Body Region	Scanner	No. of Patients	Dose Mode	DLP (mGy cm)		
					Mean DLP	Standard Deviation	Proposed NDRLs
<i>Parathyroid</i>	Neck	T	19	Moderate	66	20	170
	Neck	T16	42	Moderate	120	36	170
<i>Octreotide</i>	Abdomen	T16	15	Moderate	280	97	240
	Abdo/Pelvis	T16	14	Moderate	204	109	240
	Chest/Abdo/Pelvis	T16	32	Moderate	377	164	240
	Head/Chest/Abdo/Pelvis	T16	10	Moderate	373	151	240
<i>Cardiac</i>	Heart	T16	2889	Low	34	1	34
<i>PET/CT</i>	Whole/half body	PET	1192	Moderate	346	164	400*

*Based on half body scan

Low - Attenuation Correction, **Moderate** - Localisation

Results (cont..)

Figure 1: Mean Dose Length Product (DLP) data for Bone SPECT/CT Lumbar Spine examinations in the four dose modes.



Discussion

- The proposed NDRLs⁶ specify the examination type and the scan purpose, but the details of the body region are not given
- Only Octreotide scans have mean DLP greater than the proposed NDRL
 - ✓ low numbers, patient height/weight
- T16 scanner tends to give higher DLPs than the T scanner
 - ✓ further optimisation of doses required
 - ✓ technology difference (relative tube capabilities and detector sizes)
- **Figure 1** clearly shows the importance of dividing the data according to dose mode
- Mean DLP PET/CT (half and whole body) was less than proposed NDRLs⁶ (based on the half body only)

Conclusion

- Patient dosimetry for NMCT presents a number of difficulties which may not be encountered for Diagnostic Radiology CT
 - ✓ Dependence on paper records (CRIS does not provide all information)
 - ✓ Limited number of examinations available due to frequency of examinations and division of data
- Further improvements are planned to capture more data electronically through the CRIS system
- This system provides a useful basis for setting up LDRLs and hence a baseline for attempts at optimisation of NMCT doses

References

- 1) The Ionising Radiation (Medical Exposure) Regulations 2000. SI 2000/1059. London: The Stationery Office; 2000
- 2) European Community. Council Directive 2013/59/EURATOM. Laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation. *Off J Eur Union*. 2013 [Cited 29 September 2016]; Available from: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2014:013:0001:0073:EN:PDF>
- 3) ARSAC. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. Administration of Radioactive Substances Advisory Committee. 2016.
- 4) Etard C, Celier D, Roch P, Aubert B. National survey of patient doses from whole-body FDG PET-CT examinations in France in 2011, *Radiat Prot Dosimetry* 2012; **152**: 334-338. doi: <http://dx.doi.org/10.1093/rpd/ncs066>
- 5) Jallow N, Christian P, Sunderland J, Graham M, Hoffman JM, Nye JA. Diagnostic Reference Levels of CT Radiation Dose in Whole-Body PET/CT. *J Nucl Med* 2016; **57**: 238-241. doi: <http://dx.doi.org/10.2967/jnumed.115.160465>
- 6) Bebbington N, Burniston M, Edyvean S, Fraser L, Julyan P, Parkar N, et al. UK national reference doses for CT scans performed in hybrid imaging studies. *J Nucl Med* 2016; **57**; no. supplement 2 **594**. Available from: http://jnm.snmjournals.org/content/57/supplement_2/594?legid=jnumed%3B57%2Fsupplement_2%2F594&related-urls=yes&trendmd-shared=0

Acknowledgements

- Erin Ross, Principal Physicist, Nuclear Medicine Department
- Elizabeth Larkin, Consultant Clinical Scientist, RRPPS
- Nuclear Medicine technologists at QEHB (particularly Samantha Holt and Kenneth Parker)
- Sophie Bissel, Trainee Clinical Scientist, Nuclear Medicine Department

Thank you for your attention
Any Questions?



NB: This work will be submitted for publication imminently

Contact Information

Ngonidzashe Michael Katsidzira
NgonidzasheMichael.Katsidzira@uhb.nhs.uk

Matthew Gardner
Matthew.Gardner@uhb.nhs.uk